Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder CancerWei Shen Tan, Vignesh T. Packiam, Ian M. McElree et al.|European Urology Oncology|2023Cited by 38
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancerJacob Taylor, Yair Lotan, Drupad Annapureddy et al.|British Journal of Urology|2024Cited by 27
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesDrupad Annapureddy, Yair Lotan, Jacob Taylor et al.|European Urology Focus|2025Cited by 2
NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORTJacob Taylor, William C. Huang, Drupad Annapureddy et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 1
IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDYDrupad Annapureddy, Yair Lotan, Jacob Taylor et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 1